© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BNB Plus Corp. (BNBX) stock declined over -5.76%, trading at $0.56 on NASDAQ, down from the previous close of $0.59. The stock opened at $0.57, fluctuating between $0.48 and $0.62 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 20, 2026 | 0.59 | 0.62 | 0.48 | 0.56 | 35.68M |
| Apr 17, 2026 | 0.58 | 0.61 | 0.56 | 0.59 | 157.11K |
| Apr 16, 2026 | 0.63 | 0.65 | 0.52 | 0.58 | 416.88K |
| Apr 14, 2026 | 0.69 | 0.69 | 0.56 | 0.58 | 2.82M |
| Apr 13, 2026 | 0.56 | 0.57 | 0.53 | 0.56 | 21.94K |
| Apr 10, 2026 | 0.63 | 0.63 | 0.57 | 0.58 | 62.09K |
| Apr 09, 2026 | 0.60 | 0.65 | 0.60 | 0.62 | 110.32K |
| Apr 08, 2026 | 0.64 | 0.65 | 0.62 | 0.63 | 18.58K |
| Apr 07, 2026 | 0.63 | 0.65 | 0.60 | 0.62 | 37.08K |
| Apr 06, 2026 | 0.65 | 0.65 | 0.63 | 0.63 | 10.56K |
| Apr 02, 2026 | 0.65 | 0.67 | 0.63 | 0.66 | 6.6K |
| Apr 01, 2026 | 0.68 | 0.69 | 0.63 | 0.65 | 14.33K |
| Mar 31, 2026 | 0.65 | 0.67 | 0.62 | 0.64 | 8.64K |
| Mar 30, 2026 | 0.69 | 0.70 | 0.66 | 0.66 | 5.12K |
| Mar 27, 2026 | 0.66 | 0.69 | 0.62 | 0.69 | 23.06K |
| Mar 25, 2026 | 0.73 | 0.75 | 0.65 | 0.69 | 129.86K |
| Mar 24, 2026 | 0.80 | 0.80 | 0.73 | 0.73 | 14.45K |
| Mar 23, 2026 | 0.80 | 0.85 | 0.75 | 0.79 | 198.29K |
| Mar 20, 2026 | 0.77 | 0.84 | 0.74 | 0.81 | 92.53K |
| Mar 19, 2026 | 0.80 | 0.80 | 0.74 | 0.80 | 4K |
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
| Employees | 46 |
| Beta | 0.7 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |